Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (604)	1/29/2002 10:42:37 AM
From: tuck	Read Replies (2) \| Respond to of 1005

Not much meat here, but at least it's popsitive: >>CHAPEL HILL, N.C., Jan. 29 /PRNewswire-FirstCall/ -- POZEN Inc. (Nasdaq: POZN - news) announced today that the preliminary results of the company's first carcinogenicity study for its lead product candidate, MT 100, indicate that MT 100 is not carcinogenic in the test species, transgenic p53 mice. Results from the ongoing two-year rat carcinogenicity study will be available in 2003. John R. Plachetka, Pharm.D., chairman, president and chief executive officer of POZEN, said, ``We are very pleased with these favorable preliminary data. As part of our ongoing dialogue with the FDA concerning this issue, we will submit the study report within the next few weeks.'' MT 100 is being developed as an oral, first-line treatment for migraine pain and associated symptoms. The effectiveness of the product candidate has been demonstrated in numerous Phase II and Phase III clinical studies involving thousands of patients. Last year the company announced that MT 100 provided comparable efficacy with fewer side effects when tested against Imitrex®, the worldwide market leader.<< snip Cheers, Tuck